Orthomolecular Medicine News Service, May 7, 2015
by Atsuo Yanagisawa, MD, PhD
(OMNS May 7, 2015) Immunization of adolescent girls with the human papilloma-virus (HPV) vaccine was initiated with the intention to prevent uterine and cervical cancer. The first HPV vaccine, called “Gardasil” (Merck) was approved in 2006, and a second vaccine called “Cervarix” (GSK) was introduced in 2007. By the end of 2013, approximately 130 million doses of Gardasil and 44 million doses of Cervarix had been distributed worldwide. In 2010, both vaccines were widely given to Japanese girls. In April 2013, Japan added both HPV vaccines to their government recommended vaccination schedule.
High incidence of side effects
In June 2013, only 2 months after the law was issued, the Japanese government suspended the recommendation for these vaccines. A new study reported that the adverse events of Gardasil and Cervarix were 1.7 to 3.6 times higher than other vaccines. The government task force analyzed reports of HPV vaccine injuries. They examined 2,500 cases and found 617 (25%) cases to be “serious.”
Amazingly, the official task force then issued this statement:
“We find no physical cause for the alleged and presumed adverse reactions in those vaccinated girls, so we cannot recommend any specific therapy. We conclude that their so-called adverse reactions are psychosomatic. The government should provide counseling to the girls so that they may be freed from their psychosomatic reactions.”
Severity of side effects
When other health experts re-evaluated those cases, they determined 1,112 (44%) to be serious. The initial onset of symptoms occurred several weeks to a year after the HPV vaccine was given. They included: headache, dizziness, muscle weakness and pain, nausea, hypersomnia, learning difficulty, impaired writing, photophobia, tremors of arms, feet and fingers, joint pain, irregular menstruation, gait disturbance, memory loss, skin eczema and acne.
Girls who had adverse effects from the HPV vaccine were variously diagnosed with:
- Higher brain dysfunction
- Guillain-Barré syndrome
- Multiple sclerosis
- ADEM: acute disseminated encephalomyelitis
- SSPE: subacute sclerosing panencephalitis
- CRPS: Complex regional pain syndrome
- POTS: Postural orthostatic tachycardia syndrome
- Anti-phospholipid antibody syndrome
- SLE: systemic lupus erythematosus
- Rheumatoid arthritis
- Chronic fatigue syndrome
- Cushing’s syndrome (exposure to high level of cortisol)
- Hashimoto’s disease (immune system attacks the thyroid)
- Hyperprolactinemia (high prolactin, induces breast development and lactation)
Laboratory findings included:
- Normal blood chemistry
- No inflammatory finding in the blood
- Increased pro-inflammatory cytokines in the spinal fluid (IL-2, IL-10, TNF-à)
- Reduced brain blood flow by perfusion scintigraphy
- High leukocyte sensitivity against aluminum.
HPV vaccine contains toxic aluminum
Vaccines often contain an adjuvant, which is an additional chemical added to provoke the body’s immune response to the vaccine. The HPV vaccines contained an adjuvant that consisted of an aluminum compound, amorphous aluminum hydroxyphosphate sulfate (AAHS).
Current research strongly implicates aluminum adjuvants in various inflammatory neurological and autoimmune disorders in both humans and animals. For example, a recent research paper explained that nanomaterials such as this aluminum adjuvant can be transported by immune system cells first into the blood, lymph nodes, and spleen, and in some cases may penetrate into the brain.  This type of access throughout the body is potentially life-threatening. The brain symptoms are often the most delayed because of the time the aluminum takes to travel from the blood through the blood-brain-barrier into the brain.
Aluminum accumulates in neurons in the brain, and it is toxic to neurons, causing a variety of pathological conditions. It inhibits uptake of dopamine and serotonin, which are important neurotransmitters in the brain. Aluminum toxicity is a known factor in Alzheimer’s disease, and may contribute symptoms of Parkinson’s disease. Dementia resulting from kidney dialysis is related to aluminum and results in memory loss, loss of coordination, confusion and disorientation. In animal experiments, rabbits given aluminum showed difficulty in memory retention and difficulty in learning.
The timing and appearance of adverse effects and symptoms of the HPV vaccines vary for each patient. These symptoms differ from anything that we have previously experienced. Unfortunately, governments and medical professions have not faced the problem proactively. Although treatment with orthomolecular medicine has been helpful in many cases, it is not always adequate to return the patient to normal. In order to establish an effective protocol, scientists and clinicians must work together.
The onset of adverse effects from HPV vaccines arrives several months to a year or more after the injection. This delay makes it very difficult to link the symptoms with the HPV vaccine. In Japan, more than 1,200 girls have been registered as “severe cases” and more patients are registered every day. We estimate more than 100,000 unrecognized cases of mild to moderate adverse effects in girls vaccinated with HPV. The symptoms are commonly seen as fatigue, muscle pain, headache, learning disturbance, difficulty in awakening, hypersomnia, irregular menstruation, among others.
Doctors should be made aware of HPV vaccine adverse effects. Unfortunately, there is no evidence about the effectiveness of cervical cancer prevention by the HPV vaccines. Therefore, in my opinion as a concerned physician, we should discontinue this harmful HPV vaccine as soon as possible.
I would like to thank Dr. Damien Downing, president of the British Society for Ecological Medicine, and Dr. Claus Hancke, FACAM, specialist in general medicine, for their very important contributions to this paper.
(Dr. Atsuo Yanagisawa is president of the Japanese College of Intravenous Therapy. Previously he was Professor of Clinical Medicine at the Kyorin University School of Health Sciences, and Professor of Clinical Cardiology at Kyorin University Hospital. Dr. Yanagisawa is the author of 140 scientific papers in English and Japanese and has published several books. This OMNS is a condensed version of Dr. Yanagisawa’s presentation at the 2015 Orthomolecular Medicine Today conference in Toronto, Canada http://www.orthomed.org/omt/omt.html )
OMNS free subscription link http://orthomolecular.org/subscribe.html
OMNS archive link http://orthomolecular.org/resources/omns/index.shtml